Evidence map›Paper›PMID 41479029›Full record

ReviewResults and problems in cell differentiation2026

Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.

Stanley C Jordan, Noriko Ammerman, Edmund Huang, Ashley Vo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Results and problems in cell differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stanley C JordanComprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA, USA. stan.jordan@cshs.org.
Noriko AmmermanComprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
Edmund HuangComprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
Ashley VoComprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-mediated rejection (AMR) is now recognized as the primary cause of the decline of functional integrity and ultimately, graft failure in kidney transplants. Evolving understanding of effectors responsible for B-cell activation and plasma cell biology has led to the informed design of new therapeutics. Currently, several novel agents with varying mechanisms of action have emerged. These include imlifidase, FcRn inhibitors, anti-cytokine (IL-6/IL-6R) therapies, and plasma cell-directed therapies, especially anti-CD38s. As our understanding of critical effector pathways responsible for ARM grows, we now know that no single agent can control all facets of antibody generation and injury. The future of antibody-directed therapeutics will require protocols consisting of multiple agents positioned in a logical sequence to rapidly and durably remove pathogenic DSAs and block their re-emergence.

Indexed as

Graft RejectionKidney TransplantationAllograftsHumansAntibody-dependent cellular cytotoxicity (ADCC)Antibody-mediated rejectionAnti-CD20Anti-CD38B cellsComplement-dependent cytotoxicity (CDC)FcRn inhibitors anti-IL-6/IL-6RImlifidaseKidney transplantationPlasma cells

Identifiers

PMID41479029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.